CA-SOURCE-PHOTONICS
7.12.2020 15:33:13 CET | Business Wire | Press release
Source Photonics, a leading vendor of optical connectivity products used in telecommunication systems and data communications networks, today announces the release of its new 100G ZR4 QSFP28 transceiver for 80km high-speed data center interconnects and routing applications. Leveraging the widely deployed 4 x 25G NRZ optics, 100G ZR4 QSFP28 is the latest addition to the company’s dominant 100G product lines among its leading 100/200/400G portfolio of single-mode transceivers for datacenter and routing applications.
Cloud traffic continues to drive data center growth and the industry requires cost-effective and high-bandwidth interoperable solutions. The Source Photonics 100G ZR4 QSFP28 is cost optimized and low power transceiver supporting 100G Ethernet for extended reach up to 80km transmission that provides point to point network connectivity solutions between data centers or central offices without the need to deploy either complicated, power hungry, and expensive coherent solution or legacy CFP/CFP2 interfaces. The 100G ZR4 QSFP28 alleviates the fiber shortage bottlenecks and enables hyperscale cloud operators to scale their network.
The transceiver is in QSFP28 form factor, the smallest for 100G 80km solution. It is fully compliant with the industry standard QSFP28 and related MSA described in the latest SFF-8665/8636 and digital diagnostic functions are available through an I2C interface. It also complies with IEEE 802.3 100GBASE-ZR4 related specifications. In addition, the module supports standard KR4 FEC (Forward Error Correction) baud rates which will help receive side detect and correct bit errors and improve the overall quality of the link. The 100G ZR4 QSFP28 transceiver is capable to operate over up to 80km point-to-point link without the need for optical amplification and dispersion compensation.
Source Photonics will showcase a product demonstration of the 100G ZR4 QSFP28 transceiver for 80km optical transmission in its virtual booth, in addition to live booth activities, and informative video content during the ECOC 2020 Virtual Exhibition on December 7 to 9.
Source Photonics is currently sampling its 100G ZR4 QSFP28 product, in addition to its latest 100G ER4 and 400G ER8 transceivers. Source Photonics is in full production of its other products for data center and routing applications such as 100G LR4/ER4 Lite, 100G DR1/FR1/LR1, and 400G DR4/FR4/LR4/LR8 transceivers.
For more information about Source Photonics and its product offering, please visit www.sourcephotonics.com .
About Source Photonics :
Source Photonics is a leading provider of innovative and reliable optical communications technology that enables communications and connectivity in datacenters, metro, and access networks. We add value to our customers by developing next-generation solutions that enable their growth by meeting the rapidly increasing demands of cloud infrastructure, wireless communications, routing, and fiber-to-the-premises applications worldwide. Source Photonics has key R&D and manufacturing facilities in California, Taiwan, Chengdu, and Jintan, China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005591/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom